Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie (ABBV) is currently conducting a Phase 2 clinical study titled A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination With Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer. The study aims to assess adverse events and changes in disease activity in adult participants with unresectable metastatic colorectal cancer.
The intervention being tested is ABBV-400, an investigational drug administered intravenously. It is being tested in combination with Fluorouracil, Folinic Acid, and Bevacizumab (FFB), which are approved treatments for this type of cancer.
The study is designed as an interventional trial with a randomized allocation and a sequential intervention model. It is unmasked, meaning both participants and researchers know which treatment is being administered. The primary purpose is treatment-focused.
The study began on November 12, 2023, with an estimated completion date three years from the start. The last update was submitted on June 24, 2025, indicating ongoing recruitment and data collection.
This study could significantly impact AbbVie’s stock performance by potentially introducing a new treatment option for metastatic colorectal cancer. Positive results may boost investor confidence, especially in comparison to competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.